Polymer factor ix moiety conjugates
AssigneeNektar Therapeutics
InventorsMary J. Bossard, Gayle Stephenson
Life of this patent
Estimating the term…
Abstract
Conjugates of a Factor IX moiety and one or more water-soluble polymers are provided. Typically, the water-soluble polymer is poly(ethylene glycol) or a derivative thereof. Also provided (among other things) are compositions comprising the conjugates, methods of making the conjugates, and methods of administering to a patient compositions comprising the conjugates.
Claims42
A conjugate comprising a water-soluble polymer covalently attached to a Factor IX polypeptide via a thiol group of a cysteine residue contained within the Factor IX polypeptide, where the Factor IX polypeptide is selected from Factor IX and Factor IXa and the Factor IX polypeptide has optionally been modified to include the cysteine residue to which the water-soluble polymer is covalently attached.
A conjugate comprising a water-soluble polymer covalently attached to a Factor IX polypeptide via a thioether linkage, where the Factor IX polypeptide is selected from Factor IX and Factor IXa and the Factor IX polypeptide has optionally been modified to include a cysteine residue to which the water-soluble polymer is covalently attached via the thioether linkage.
A composition comprising a plurality of monoPEGylated or diPEGylated Factor IX polypeptide conjugates, wherein the Factor IX polypeptide is selected from Factor IX and Factor IXa.
A composition comprising conjugates having one or more of the same poly(ethylene glycol)s covalently attached to a Factor IX polypeptide selected from Factor IX and Factor IXa at one or more particular attachment sites, wherein the composition is free from positional isomers of the conjugates.
The composition of claim. 21, wherein each poly(ethylene glycol) is terminally capped with methoxy.
Dependencies are inferred from the claim text.